ALLOB
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tibial Fracture
Conditions
Tibial Fracture
Trial Timeline
Jan 8, 2021 → Mar 31, 2024
NCT ID
NCT04432389About ALLOB
ALLOB is a phase 2 stage product being developed by ICON plc. for Tibial Fracture. The current trial status is unknown. This product is registered under clinical trial identifier NCT04432389. Target conditions include Tibial Fracture.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04432389 | Phase 2 | UNKNOWN |
Competing Products
2 competing products in Tibial Fracture
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| InductOs | Pfizer | Approved | 84 |
| CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 | Pfizer | Phase 2 | 51 |